Biomarkers for Early Complications After Hematopoietic Stem Cell Transplantation

被引：12

作者：

Rowan, Courtney M. ^{[1
]}

Paczesny, Sophie ^{[2
,3
]}

机构：

[1] Indiana Univ Sch Med, Dept Pediat, Div Crit Care, 705 Riley Hosp Dr,Room 4900, Indianapolis, IN 46202 USA

[2] Indiana Univ Sch Med, Dept Pediat, Melvin & Bren Simon Canc Ctr, 1044 West Walnut St,Room R4-425, Indianapolis, IN 46202 USA

[3] Indiana Univ Sch Med, Dept Microbiol Immunol, Melvin & Bren Simon Canc Ctr, 1044 West Walnut St,Room R4-425, Indianapolis, IN 46202 USA

来源：

CLINICS IN LABORATORY MEDICINE | 2019年 / 39卷 / 01期

关键词：

Biomarkers; Hematopoietic stem cell transplantation; Proteomics; Graft versus host disease; VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; HEPATIC VENOOCCLUSIVE DISEASE; PLASMA BIOMARKERS; THROMBOTIC MICROANGIOPATHY; PREDICTIVE-VALUE; CLINICAL-TRIALS; RISK; ST2; MORTALITY;

D O I：

10.1016/j.cll.2018.10.005

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Advances in the field of omics have led to a significant expansion in biomarkers identified for complications after hematopoietic stem cell transplantation (HSCT). Biomarkers can offer an effective method for early identification of a specific disease and can be used to guide therapies. Ongoing investigations to discover biomarkers for acute graft-versus-host disease as well as other post-HSCT complications may improve early diagnosis, prognosis, and the development of new therapeutic targets. The authors review the most recent and validated diagnostic, prognostic, predictive, and response to treatment biomarkers for early complications following HSCT consistent with 2014 NIH consensus on biomarker criteria.

引用

页码：61 / +

页数：13

共 47 条

[1] Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT
Abu Zaid, Mohammad
Wu, Juan
Wu, Cindy
Logan, Brent R.
Yu, Jeffrey
Cutler, Corey
Antin, Joseph H.
Paczesny, Sophie
Choi, Sung Won
[J]. BLOOD, 2017, 129 (02) : 162 - 170
[2] Biomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation
Akil, Ayman
Zhang, Qing
Mumaw, Christen L.
Raiker, Nisha
Yu, Jeffrey
de Mendizabal, Nieves Velez
Haneline, Laura S.
Robertson, Kent A.
Skiles, Jodi
Diaz-Ricart, Maribel
Carreras, Enric
Renbarger, Jamie
Hanash, Samir
Bies, Robert R.
Paczesny, Sophie
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (10) : 1739 - 1745
[3] Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network
Alousi, Amin M.
Weisdorf, Daniel J.
Logan, Brent R.
Bolanos-Meade, Javier
Carter, Shelly
DiFronzo, Nancy
Pasquini, Marcelo
Goldstein, Steven C.
Ho, Vincent T.
Hayes-Lattin, Brandon
Wingard, John R.
Horowitz, Mary M.
Levine, John E.
[J]. BLOOD, 2009, 114 (03) : 511 - 517
[4] Epidermal Elafin Expression Is an Indicator of Poor Prognosis in Cutaneous Graft-versus-Host Disease
Brueggen, Marie-Charlotte
Petzelbauer, Peter
Greinix, Hildegard
Contassot, Emmanuel
Jankovic, Dragana
French, Lars
Socie, Gerard
Rabitsch, Werner
Kuzmina, Zoya
Kalhs, Peter
Knobler, Robert
Stingl, Georg
Stary, Georg
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 (04) : 999 - 1006
[5] Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
Chaidos, Aristeidis
Patterson, Scott
Szydlo, Richard
Chaudhry, Mohammed Suhail
Dazzi, Francesco
Kanfer, Edward
McDonald, Donald
Marin, David
Milojkovic, Dragana
Pavlu, Jiri
Davis, John
Rahemtulla, Amin
Rezvani, Katy
Goldman, John
Roberts, Irene
Apperley, Jane
Karadimitris, Anastasios
[J]. BLOOD, 2012, 119 (21) : 5030 - 5036
[6] Phase 1 multicenter trial of brentuximab vedotin for steroid- refractory acute graft-versus-host disease
Chen, Yi-Bin
Perales, Miguel-Angel
Li, Shuli
Kempner, Maria
Reynolds, Carol
Brown, Jami
Efebera, Yvonne A.
Devine, Steven M.
El-Jawahri, Areej
McAfee, Steven L.
Spitzer, Thomas R.
Soiffer, Robert J.
Ritz, Jerome
Cutler, Corey
[J]. BLOOD, 2017, 129 (24) : 3256 - 3261
[7] Expression of CD30 in patients with acute graft-versus-host disease
Chen, Yi-Bin
McDonough, Sean
Hasserjian, Robert
Chen, Heidi
Coughlin, Erin
Illiano, Christina
Park, In Sun
Jagasia, Madan
Spitzer, Thomas R.
Cutler, Corey S.
Soiffer, Robert J.
Ritz, Jerome
[J]. BLOOD, 2012, 120 (03) : 691 - 696
[8] Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome
Coppell, Jason A.
Richardson, Paul G.
Soiffer, Robert
Martin, Paul L.
Kernan, Nancy A.
Chen, Allen
Guinan, Eva
Vogelsang, Georgia
Krishnan, Amrita
Giralt, Sergio
Revta, Carolyn
Carreau, Nicole A.
Iacobelli, Massimo
Carreras, Enric
Ruutu, Tapani
Barbui, Tiziano
Antin, Joseph H.
Niederwieser, Dietger
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : 157 - 168
[9] Prediction of Veno-Occlusive Disease Using Biomarkers of Endothelial Injury
Cutler, Corey
Kim, Haesook T.
Ayanian, Shake
Bradwin, Gary
Revta, Carolyn
Aldridge, Julie
Ho, Vincent
Alyea, Edwin
Koreth, John
Armand, Philippe
Soiffer, Robert
Ritz, Jerome
Richardson, Paul G.
Antin, Joseph H.
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (08) : 1180 - 1185
[10] Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease
Ferrara, James L. M.
Harris, Andrew C.
Greenson, Joel K.
Braun, Thomas M.
Holler, Ernst
Teshima, Takanori
Levine, John E.
Choi, Sung W. J.
Huber, Elisabeth
Landfried, Karin
Akashi, Koichi
Vander Lugt, Mark
Reddy, Pavan
Chin, Alice
Zhang, Qing
Hanash, Samir
Paczesny, Sophie
[J]. BLOOD, 2011, 118 (25) : 6702 - 6708

← 1 2 3 4 5 →